VR drug discovery makes precision therapy a reality
ChimeraX, virtual reality software developed at the UCSF Resource for Biocomputing, Visualization and Informatics, is now the tool of choice for computational structural biologists in the School of Pharmacy. The Jacobson Lab recently used ChimeraX to find a promising new cure for a drug-resistant case of pediatric leukemia.
Condition: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Intervention: Biological: AUTO1 Sponsor: Autolus Limited Recruiting
Conditions: Acute Myeloid Leukemia, in Relapse; Myelodysplastic Syndromes Intervention: Drug: CB-5339 Sponsor: Cleave Therapeutics, Inc. Not yet recruiting
Publication date: Available online 27 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Tengteng Yu, Yan Xu, Gang An, Yu-Tzu Tai, Matthew Ho, Zengjun Li, Shuhui Deng, Dehui Zou, Zhen Yu, Mu Hao, Kenneth C. Anderson, Lugui Qiu
Publication date: Available online 26 May 2020Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Prajwal Dhakal, Elizabeth Lyden, E Muir Kate-Lynn, Zaid S. Al-Kadhimi, Lori J. Maness, Krishna Gundabolu, Vijaya Raj Bhatt
Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed. Recent research has identified that CLL1 is highly expressed on AML leukemia stem cells and blasts cells but not on normal hematopoietic stem cells. In this case report, we treated a secondary AML patient wi...
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has increased the cure rate for these cancers from 10 to 40%. Two second-generation anti-CD19 CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel, have been approved for use in patients, and the approval of a third product, lisocabtagene maraleucel, is expected in 2020. The commercial availability of the first two products has facilitated the development of real-world experience in treating relapsed or refractory aggressive B-cell lymphomas, she...
DiscussionAs part of the HARMONY Alliance, the pilot Delphi aims to define a core outcome set in AML on the basis of a multi-stakeholder consensus. Such a core outcome set will help to allow consistent comparison of future clinical trials and real-world evidence research and ensures that appropriate outcomes valued by a range of stakeholders are measured within future trials.
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment of CML patients having gatekeeper mutation T315I, which is resistant to the first and second generation of TKIs, namely, imatinib, nilotinib, dasatinib, and bosutinib. Multiple unbiased screening from our lab and others have identified ponatinib as most cardiotoxic FDA approved TKI among the entire FDA approved TKI family (total 50+).
ConclusionThe introduction of a protocol promoting restrictive use of EAT resulted in reduction of carbapenem and vancomycin use and appears to be safe in AML or high-risk MDS patients with febrile neutropenia during chemotherapy or SCT.
Acute myeloid leukemia (AML) represents a malignant disorder of the hematopoietic system that is mainly characterized by rapid proliferation, dysregulated apoptosis, and impaired differentiation of leukemic blasts. For several decades, the diagnostic approach in AML was largely based on histologic characteristics with little impact on the treatment decision-making process. This perspective has drastically changed within the past years due to the advent of novel molecular technologies, such as whole genome next-generation sequencing (NGS), and the resulting knowledge gain in AML biology and pathogenesis. After more than fou...